Mr. Andrew Schutte reports

REPLICEL LIFE SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS AS FOCUS SHIFTS TOWARDS COMMERCIALIZATION

RepliCel Life Sciences Inc. has appointed Jamie Mackay to the company's board of directors. Mr. Mackay is currently the CEO of Mackay Developments and founder of Wheelhaus, Fireside Resorts and Vurtical. Jamie has extensive experience in large commercial, residential, and mixed-use real estate developments across the United States. Jamie, as a seasoned entrepreneur, has successfully managed numerous private startups. Having engaged with numerous entities across many different sectors as both an investor and as a member of management, Jamie brings a unique perspective. "Jamie has been integral in assisting management in laying groundwork as RepliCel prepares to commercialize multiple products. It has been a pleasure working with Jamie and I am excited to have him join the Board of Directors," Andrew Schutte President and CEO stated. "Jamie's expertise is vital as RepliCel transitions to a commercial entity."

About RepliCel Life Sciences

RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. These cell therapy product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles.

The Company's cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical study evaluating efficacy for the treatment of male and female hair loss due to androgenetic alopecia. This ongoing study is being funded by Shiseido Company Limited pursuant to a license agreement which has now been terminated but is the subject of an arbitration regarding Shiseido's rights to the product for Asia. RepliCel maintains the undisputed rights to RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel maintains the rights to these products outside of Greater China.

RepliCel has also developed a proprietary injection device (DermaPreciseTM) and related consumables, which is expected to improve the administration of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights for the DermaPrecise(TM) device and consumables in Greater China for dermatology applications and is expected to first launch the product in Hong Kong upon it being approved for market launch in either the United States or Europe. MainPointe Pharmaceuticals has an exclusive distribution agreement for the DermaPrecise(TM) device and consumables in the United States, subject to income. MainPointe is expected to fund the FDA approval process in the United States.